With 1.47 million shares changed hands, the volume of the stock remained lighter than its average volume of 4.68 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.615 whereas the lowest price it dropped to was $4.45. The 52-week range on HUMA shows that it touched its highest point at $9.97 and its lowest point at $2.69 during that stretch. It currently has a 1-year price target of $13.14. Beta for the stock currently stands at 1.30.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HUMA was up-trending over the past week, with a rise of 11.41%, but this was up by 29.66% over a month. Three-month performance dropped to -8.75% while six-month performance fell -45.03%. The stock gained 71.91% in the past year, while it has lost -9.11% so far this year. A look at the trailing 12-month EPS for HUMA yields -1.34 with Next year EPS estimates of -0.86. For the next quarter, that number is -0.25. This implies an EPS growth rate of -26.30% for this year and 36.05% for next year.
Float and Shares Shorts:
At present, 119.84 million HUMA shares are outstanding with a float of 104.40 million shares on hand for trading. On 2024-12-31, short shares totaled 29.62 million, which was 2302.0001 higher than short shares on 1732838400. In addition to Dr. Laura E. Niklason M.D., Ph.D. as the firm’s Founder, President, CEO & Director, Mr. Dale A. Sander serves as its CFO, Chief Corporate Development Officer & Treasurer.
Institutional Ownership:
Through their ownership of 0.30185 of HUMA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, HUMA reported revenue of $0.0 and operating income of -$30233000.0. The EBITDA in the recently reported quarter was -$27510000.0 and diluted EPS was -$0.33.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HUMA since 2 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With HUMA analysts setting a high price target of 25.0 and a low target of 6.0, the average target price over the next 12 months is 13.14286. Based on these targets, HUMA could surge 444.66% to reach the target high and rise by 30.72% to reach the target low. Reaching the average price target will result in a growth of 186.34% from current levels.
Analysts have provided yearly estimates in a range of -$1.05756 being high and -$1.49554 being low. For HUMA, this leads to a yearly average estimate of -$1.35667. Based on analyst estimates, the high estimate for the next quarter is -$0.24 and the low estimate is -$0.27. The average estimate for the next quarter is thus -$0.25.
